A Trial of Grazax in Subjects With Hayfever
Launched by ALK-ABELLÓ A/S · Jan 11, 2007
Trial Information
Current as of June 18, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • History of grass pollen allergy
- • Positive skin prick test to grass
- • Positive specific IgE to grass
- • Exclusion Criteria
- • FEV1 \<70% of predicted value
About Alk Abelló A/S
ALK-Abelló A/S is a global biopharmaceutical company specializing in the development of innovative allergy immunotherapy treatments. With a strong commitment to improving patient outcomes, ALK focuses on research and development of products that address various allergic conditions, including asthma, rhinitis, and food allergies. Leveraging advanced scientific expertise and a robust pipeline of therapies, ALK aims to enhance the quality of life for individuals affected by allergies while adhering to the highest standards of safety and efficacy in clinical trial practices. The company is dedicated to advancing the field of allergy treatment through collaboration and innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Iowa City, Iowa, United States
Patients applied
Trial Officials
Kim Simonsen, MD
Study Director
ALK-Abelló A/S
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials